Pharmafile Logo

Dr. Martine Dehlinger-Kremer of SynteractHCR Nominated Chair of Childrens Medicines Working Party for European Forum for Good Clinical Practice

November 9, 2016 – Pharmaceutical –

SAN DIEGO – November 9, 2016 – SynteractHCR, a full-service, international contract research organization (CRO), is announcing that its vice president for global medical and regulatory affairs, Dr. Martine Dehlinger-Kremer, has recently been appointed as the Chair of the European Forum for Good Clinical Practice (EFGCP) Childrenís Medicines Working Party. As such, Dehlinger-Kremer, is now also a member of the EFGCP Board.

Dehlinger-Kremer will work with the Co-Chair of the EFGCP Childrenís Medicines Working Party, Dimitrios Athanasiou. Athanasiou is head of patient advocacy of Muscular Dystrophy Association Hellas (MDA Hellas) Greece; board member of United Parent Projects Muscular Dystrophy (UPPMD), the worldwide group of Duchenne Patient and Parent Organisations and the EFGCP and an EMA-nominated expert for DMD.

EFGCP is a non-profit organization established by and for individuals with a professional involvement in the conduct of biomedical research. Founded during a conference at the European Parliament in 1993 with the support of the European Commission, The EFGCP Children’s Medicines Working Party facilitates multi-stakeholder discussion in Europe on best practices and standards in pediatric drug development needed for better medicines for children. Members include representatives from pharmaceutical companies, pediatricians and academia, regulatory authorities, patients’ and parents’ organizations and ethics committees.

Dr. Martine Dehlinger-Kremer draws on over 30 years experience in the clinical research industry and has contributed to the global development of numerous pharmaceutical products and devices, including participating in 100+ NDAs/MAAs. She is also chair of the EUCROF Pediatric Working Group, a member of Enpr-EMA working parties and has been a frequent speaker and session chair on clinical pediatric research at EUCROF European Conference on Clinical Research, EFGCP/DIA/EMA Better Medicines for Children Conference, PHARMIG/OKIDS Conference and others.

‘Dr. Dehlinger-Kremer exemplifies our culture, at SynteractHCR, of dedication and collaboration to bring better medicines to market for patients,’ said Wendel Barr, CEO of SynteractHCR. ‘We congratulate her on the addition of this exciting, new role as she continues to work with other leaders on the forefront of pediatric drug development.’

SynteractHCR
5759 Fleet Street, Suite 100 Carlsbad, CA 92008, US